Veterinary Renal Disease Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Veterinary Renal Disease Market size was valued at USD 15.9 billion in 2023 and is predicted to reach USD 26.5 billion by 2032, showcasing growth of 5.9% from 2024 to 2032 period. The growth of this market can be attributed to factors such as rise in pet ownership and advances in animal diagnostics.
Also, rising prevalence of renal diseases in animals, growing focus on renoprotective diets of animals, and increased awareness among pet owners and veterinarians are expected to fuel the growth market. According to the report published by the International Renal Interest Society in 2023, the prevalence of CKD is estimated to be 0.5-1% in dogs and 1-3% in cats. However, it increases with age, specifically in cats with reported prevalence of 80% in the geriatric cat population. Thus, adoption of renal disease treatment and diagnosis in such population will spur the market progress.
Veterinary renal disease refers to any condition or disease affecting the kidneys of animals, including domestic pets and livestock. These conditions may involve structural abnormalities, functional disturbances, or inflammatory processes within the kidneys, leading to impaired kidney function and potential complications affecting other organ systems.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Veterinary Renal Disease Market size in 2023: | USD 15.9 Billion |
| Forecast Period: | 2024 - 2032 |
| Forecast Period 2023 - 2032 CAGR: | 5.9 |
| 2023 Value Projection: | USD 26.5 Billion |
| Historical Data for: | 2018 - 2023 |
| No of Pages: | 210 |
| Tables, Charts & Figures: | 368 |
| Segments Covered: | Type, Animal Type, Indication, and Region |
| Growth Drivers: |
|
| Pitfalls Challenges: |
|
The market based on type is segmented into treatment and diagnosis. The treatment segment accounted for majority of market share of 67.3% in 2023 and is expected to dominate throughout the analysis period.
The veterinary renal disease based on animal type is classified into bovine, canine, feline, equine, and other animal types. The feline animal type dominated the market and was valued at USD 6.7 billion in 2023.
Chronic kidney disease is a prevalent condition among aging cats, and its incidence is on the rise. This trend drives the demand for diagnostic tests, treatments, and management strategies specific to feline CKD. These factors collectively contribute to cats having the highest prevalence of veterinary renal illnesses compared to dogs, horses, and cows.
For instance, according to the data published by American Veterinary Medical Association in 2021, chronic kidney disease (CKD) in cats ranged between 2% - 20%. For cats older than 10 - 15 years, this number rise up to 30% - 80%. Thus, growing prevalence of CKD among cats along with increasing emphasis on early diagnosis is projected to accelerate the market growth.
Based on indication, the veterinary renal disease market is divided into renal failure, chronic kidney disease (CKD), renal cystitis, kidney stones, nephritis, and other indications. The renal cystitis segment accounted for significant market position and is predicted to reach USD 7.5 billion by 2032.
North America veterinary renal disease market accounted for USD 7 billion revenue in 2023 and is anticipated to grow at CAGR of 5.7% between 2024 and 2032 period.
The veterinary renal disease industry is characterized by the presence of several key players offering innovative solutions to healthcare providers. Leading companies in this market include Boehringer Ingelheim International GmbH, Zoetis Inc., and Elanco Animal Health Incorporated, among others. The strategic partnerships, mergers, and acquisitions are common strategies employed by players to expand their market presence, enhance their product portfolios, and gain a competitive advantage.
Prominent players operating in the veterinary renal disease industry include:
Market, By Type
Market, By Animal Type
Market, By Indications
The above information is provided for the following regions and countries:
Dechra Pharmaceuticals, Elanco Animal Health Incorporated, General Mills Inc., Hill's Pet Nutrition, Inc., IDEXX Laboratories, Inc., The J.M. Smucker Company, Mars Incorporated, Merck & Co., Inc., and Nestle Purina, are some of the major veterinary renal disease companies worldwide.
North America veterinary renal disease industry reached USD 7 billion in 2023 and is expected to register a commendable CAGR from 2024-2032 due to the increasing emphasis on comprehensive animal healthcare in the region.
Veterinary renal disease market size was USD 15.9 billion in 2023 and is expected to register 5.9% CAGR from 2024-2032 owing to the rise in pet ownership and advances in animal diagnostics worldwide.
The treatment segment held 67.3% share in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to the growing prevalence of kidney disorders in animals, that increases the demand for effective treatment options.